Podcast
The Glucose Never Lies® Podcast
Hosted by John Pemberton · EN
Host John Pemberton — diabetes educator, researcher, and dad living with type 1 since 2008 — explores how to think clearly about type 1 diabetes in the real world.
Each episode translates current evidence and expert practice into decisions you can use: CGM accuracy and interpretation, getting more from pumps and automated insulin delivery, movement as a glucose tool, nutrition that protects performance and enjoyment, sleep, travel, parties, and sport.
Guests include leading clinicians, researchers, and people with lived experience. Expect respectful challenge, plain language, and practical take-aways.
Note: Educational only. No therapeutic relationship or personal medical advice.
Buy the GNL a Coffee to keep us independent: https://www.buymeacoffee.com/jspfree2s
Email: john@theglucoseneverlies.com
30episodes
Episodes
Newest firstAll episodes
Episode 43: Tandem Control-IQ+ and Mobi, with Laurel Messer
4w ago01:03:59Tap to summarizeSuggest guests or get in contactA pump can be technically excellent and still deliver mediocre results, because the two settings that decide the outcome are the ones most clinicians tune last. Laurel Messer, VP of Global Medical Affairs at Tandem Diabetes Care, returns to open the GNL AID series. She and John go through the real-world data behind Control-IQ's most powerful lever, what Control-IQ+ changes for the very young and the very high dose, the new sick day and extended bolus tools, the fresh FDA clearance for pregnancy, and the Tandem Mobi. IN THIS EPISODE - Why correction factor, not basal rate or target, is the setting with the biggest real-world effect on time in range (Messer 2023, n equals 20,764) - Control-IQ+, the total daily dose range extended to 5 to 200 units, opening the system to very young children and very high insulin users - Control-IQ+, the correction factor ceiling raised from 11 to 33 mmol/L (200 to 600 mg/dL) - The new sick day hack, a temp basal that runs without leaving automation - The extended bolus, up to eight hours, for high fat meals and delayed gastric emptying - Fresh FDA clearance for Control-IQ in pregnancy, and what the CIRCUIT trial found for time in pregnancy range - The Tandem Mobi, a matchbox sized on-body pump running the same Control-IQ algorithm CHAPTERS 00:00 Introduction, launching the AID series 01:43 Welcome back, Laurel Messer 03:55 The 2023 registry paper, correction factor as the secret sauce 10:40 A basal and correction factor formula in practice 12:39 Time blocks across the day, the dusk phenomenon 15:37 Control-IQ+, wider total daily dose range 17:27 Control-IQ+, correction factor ceiling raised 20:50 Recap, basal at 50 percent, correction factor as the dial 22:36 Temp basal with automation on, the sick day hack 26:32 Extended bolus, up to eight hours 28:17 The pizza test 30:23 The science, why fat blocks insulin 32:21 FDA clearance for pregnancy 36:06 CIRCUIT trial results 44:22 Sleep Activity in pregnancy 49:14 Introducing the Tandem Mobi 53:41 Mobi minimum fill and early feedback 57:16 Takeaways, the two levers to know GUEST Laurel Messer, VP of Global Medical Affairs, Tandem Diabetes Care. Host: John Pemberton, founder of The Glucose Never Lies and a paediatric diabetes dietitian, and a person living with type 1 diabetes. LINKS (all full absolute URLs) Show notes: https://www.theglucoseneverlies.com/episode-43-tandem-control-iq-plus-mobi/ Watch on YouTube: https://youtu.be/2Zq2XALSnYA Apple Podcasts: https://podcasts.apple.com/gb/podcast/the-glucose-never-lies/id1795741144 Spotify: https://open.spotify.com/show/2MlGlz2G8LsbDnuGtAh77W AID Algorithm Optimiser: https://www.theglucoseneverlies.com/aid-system-explorer/ Previous episode: https://www.theglucoseneverlies.com/episode-42-dice-2026-highlights/ ASK GRACE Have more questions? Ask GNL Grace, a diabetes educational adviser built by a team with skin in the game. Grace gets you 80 per cent of the way there with 20 per cent of the effort; the final 20 per cent takes self-discovery, guided by human expertise and trial-and-error learning. Check out Grace at https://www.theglucoseneverlies.com/gnl-grace/ SUPPORT THIS PODCAST The Glucose Never Lies is independent by design. We take no sponsorship and no advertising, so the podcast stays answerable only to the people who listen to it. If it has been useful, you can help keep it that way: drop a one-off tip, or set up a small monthly amount to keep the show ad-free. Either way, every penny goes back into making episodes. Buy us a coffee (one-off or keep-it-ad-free): https://www.buymeacoffee.com/gnlfree FOLLOW Website: https://www.theglucoseneverlies.com/ Instagram: https://www.instagram.com/theglucoseneverlies LinkedIn: https://www.linkedin.com/company/theglucoseneverlies X: https://twitter.com/GlucoseNLies DISCLAIMER This podcast is for education only. It is not medical advice and is not a substitute for individualised care from your diabetes team. This episode reflects the independent clinical perspective of John Pemberton; Laurel Messer speaks in her role at Tandem Diabetes Care. It is not an endorsement by GNL of any product. The Glucose Never Lies is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08. DisclaimerThis podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.The Glucose Never Lies® is independent by designWe do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:Buying the GNL a Coffee:https://buymeacoffee.com/gnlfreeEnquiriesCollaboration: John Pemberton — john@theglucoseneverlies.comCreatives: Anjanee Kohli — anj@theglucoseneverlies.comFollow The Glucose Never Lies®Website: https://theglucoseneverlies.com/Instagram: https://www.instagram.com/theglucoseneverliesLinkedIn: https://www.linkedin.com/company/theglucoseneverliesLinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/X: https://twitter.com/GlucoseNLiesDisclaimer This content is for informational purposes only and does not constitute medical advice.© The Glucose Never Lies Ltd. All rights reserved.
Transcribe →
Episode 42: DICE 2026 - The Highlights
Jun 101:09:47Tap to summarizeSuggest guests or get in contactSuggest guests or get in contactJohn Pemberton was at Croke Park on 21 May for DICE — Diabetes Ireland Conference and Exhibition — Ireland's premier annual event for healthcare professionals working in diabetes. The day also saw the launch of the landmark National Policy and Services Review for diabetes in Ireland. John grabbed a microphone and seven conversations. This episode is all of them.Anjanee Kohli is Co-Director and Creative Director of The Glucose Never Lies® and the host for this episode. John Pemberton is founder of The Glucose Never Lies® and a paediatric diabetes dietitian at Birmingham Women's and Children's NHS Foundation Trust; he is also a person living with T1D. This episode reflects the independent views of both.This episode covers:Sinead Powell (Education and Support Coordinator, Diabetes Ireland): the COPE programme, emotional wellbeing in type 2 diabetes, language, stigma, and why information alone is never enoughKathy Breen (Clinical Specialist Dietitian and Dietetic Lead, National Diabetes Programme): what Language Matters looks like in practice, person-first language, and its inclusion in the new national strategyKate Gaievska (Clinical Manager for Advocacy and Research, Diabetes Ireland): why adult diabetes psychology services in Ireland are effectively non-existent, what the strategy commits to, and the long road of implementationProfessor Fidelma Dunne (University of Galway / National Clinical Trials Network in Diabetes): how clinical trials get funded, why real-world data matters, and why research is not the icing on the cakeChristine Newman (Diabetes Consultant, Galway): hybrid closed-loop in pregnancy, CGM for type 2, and the case for free glucose strips for gestational diabetesProfessor Derek O'Keefe (Consultant Physician and Professor of Medical Device Technology, UHG): Mochara, a bounded AI education tool that matched nurse and doctor performance in trials, ambient clinical documentation, intelligent dynamic triage, and what multimodal AI means for diabetes careDr Tomas Griffin (Consultant Diabetologist, Galway / DTN Ireland): what the strategy means for pump access, the DTN Ireland roadshow, and why every tier of hospital in Ireland is now starting pump therapyShow notes: https://theglucoseneverlies.com/Have more questions? Ask GNL Grace, a diabetes educational adviser built by a team with skin in the game. Grace gets you 80% of the way there with 20% of the effort; the final 20% takes self-discovery, guided by human expertise and trial-and-error learning. https://theglucoseneverlies.com/gnl-grace/DisclaimerThis podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.The Glucose Never Lies® is independent by designWe do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:Buying the GNL a Coffee:https://buymeacoffee.com/gnlfreeEnquiriesCollaboration: John Pemberton — john@theglucoseneverlies.comCreatives: Anjanee Kohli — anj@theglucoseneverlies.comFollow The Glucose Never Lies®Website: https://theglucoseneverlies.com/Instagram: https://www.instagram.com/theglucoseneverliesLinkedIn: https://www.linkedin.com/company/theglucoseneverliesLinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/X: https://twitter.com/GlucoseNLiesDisclaimer This content is for informational purposes only and does not constitute medical advice.© The Glucose Never Lies Ltd. All rights reserved.
Transcribe →
Ep 41: CGM Series Round-Up, Grace Update and John on Diabetech
May 1800:40:12Tap to summarizeSuggest guests or get in contactEvery few months, The Glucose Never Lies stops and takes stock. No single guest, no single topic: three CGM Series episodes have landed since the last round-up, Grace has a new model, and John has appeared on two podcasts that are not his own. This episode covers all of it. Anjanee Kohli is Co-Director and Creative Director of The Glucose Never Lies® and the host for this episode. John Pemberton is founder of The Glucose Never Lies® and a paediatric diabetes dietitian at Birmingham Women's and Children's NHS Foundation Trust; he is also a person living with T1D. This episode reflects the independent views of both. This episode covers:- CGM Series catch-up: episodes 38, 39, and 40 in one conversation- The IFCC glucose stress test: what it measures, the CE-versus-FDA accuracy gap, and the car crash analogy for insulin-dosing sensors- The MDI generation gap: why people on injections have had one generation of CGM while pump users have had five- What 17 early adopters actually reported about Night Low Predict and Glucose Predict on the Accu-Chek SmartGuide- Grace's new model: a 30-day free trial for everyone, then Personal at £5 a month (£50 a year) and HCP at £20 a month (£200 a year); a £5 Buy Me a Coffee sponsorship opens a free account for someone on the waiting list- The near-bankruptcy moment: flat architecture to wiki retrieval layer, cost reduced to roughly five per cent- Why Grace has no memory by design: the deliberate reasoning behind a deliberate constraint- John on Diabetech (Gary Shiner's show, hosted by Justin): CGM international testing standards- John on Tomorrow's Medicine with Arseniy Arsentyev: how Grace was built, the antibody result that started it, and what nearly ended it- AI and healthcare work: the people who adapt, the people who hide behind procedure, and what cannot be automated Show notes: https://theglucoseneverlies.com/episode-41-cgm-series-grace-diabetech/ Before this episode, John appeared on:Diabetech (Gary Shiner's show, hosted by Justin): https://youtu.be/6sxM1HOxcP4?si=2B3lHzyjSBgPKYfbTomorrow's Medicine with Arseniy Arsentyev: https://youtu.be/60MZGAk86NY?si=l3oF1J37EiI7fcCE Have more questions? Ask GNL Grace, a diabetes educational advisor built by a team with skin in the game. Grace gets you 80% of the way there with 20% of the effort; the final 20% takes self-discovery, guided by human expertise and trial-and-error learning. https://theglucoseneverlies.com/gnl-grace/ --- DisclaimerThis podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care. The Glucose Never Lies® is independent by designWe do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:Buying the GNL a Coffee: https://www.buymeacoffee.com/gnlfree EnquiriesCollaboration: John Pemberton, john@theglucoseneverlies.comCreatives: Anjanee Kohli, anj@theglucoseneverlies.com Follow The Glucose Never Lies®Website: https://theglucoseneverlies.com/Instagram: https://www.instagram.com/theglucoseneverliesLinkedIn: https://www.linkedin.com/company/theglucoseneverliesLinkedIn John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/LinkedIn Anjanee Kohli: https://www.linkedin.com/in/anjanee-kohli-chohan-1b22a217b/Instagram Anjanee Kohli: https://www.instagram.com/anjanee.dietitianX: https://twitter.com/GlucoseNLiesDisclaimerThis podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.The Glucose Never Lies® is independent by designWe do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:Buying the GNL a Coffee:https://buymeacoffee.com/gnlfreeEnquiriesCollaboration: John Pemberton — john@theglucoseneverlies.comCreatives: Anjanee Kohli — anj@theglucoseneverlies.comFollow The Glucose Never Lies®Website: https://theglucoseneverlies.com/Instagram: https://www.instagram.com/theglucoseneverliesLinkedIn: https://www.linkedin.com/company/theglucoseneverliesLinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/X: https://twitter.com/GlucoseNLiesDisclaimer This content is for informational purposes only and does not constitute medical advice.© The Glucose Never Lies Ltd. All rights reserved.
Transcribe →
Episode 40 - Accu-Chek SmartGuide: CGM Generation 2.0 for MDI | Amy Jolley | GNL Podcast
May 1100:57:40Tap to summarizeSuggest guests or get in contactPeople on MDI have had one generation of CGM technology: a sensor that tells you what your glucose is doing now, with a 15-minute trend arrow. While pump users have moved through five iterations, injection users have been waiting. The Accu-Chek SmartGuide is the first attempt at a second generation - and this episode asks whether it delivers.Amy Jolley is a Highly Specialised Dietitian, Lead Educator at the Diabetes Technology Network UK, and Lead for the Young Adult and Transition Service at Salford NHS Foundation Trust. This episode is not endorsed by Roche Diagnostics, but the experience of a healthcare professional's experience of putting 17 people onto the SmartGuide in one week, running group onboarding sessions, and asking them to come back and tell her what actually happened. Her host, John Pemberton, is founder of The Glucose Never Lies® and a person living with T1D. This episode covers:- Why MDI has been stuck at Generation 1 while pump technology moved through five iterations- Night Low Predict: RAG ratings, first-half versus second-half of the night, and how to teach it- Glucose Predict: the 45-minute action window versus the two-hour awareness window- What 17 early adopters actually reported back- How the 45-minute look ahead reduces the rage bolus- Why calibration is an educational opportunity, not a drawback- CGM market saturation and the DTN quality standard- The DTN Competency Assessment Framework: four tiers, self-assessment, a training passport for clinicians- GNL Grace in clinical practice: Amy's feedback from a specialist service supporting 700 AID usersShow notes: https://theglucoseneverlies.com/accu-chek-smartguide-mdi-cgm-series/Have more questions? Ask GNL Grace, a diabetes educational advisor built by a team with skin in the game. Grace gets you 80% of the way there with 20% of the effort; the final 20% takes self-discovery, guided by human expertise and trial-and-error learning. https://theglucoseneverlies.com/gnl-grace/---DisclaimerThis podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.The Glucose Never Lies® is independent by designWe do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:Buying the GNL a Coffee: https://www.buymeacoffee.com/gnlfreeEnquiriesCollaboration: John Pemberton, john@theglucoseneverlies.comCreatives: Anjanee Kohli, anj@theglucoseneverlies.comFollow The Glucose Never Lies®Website: https://theglucoseneverlies.com/Instagram: https://www.instagram.com/theglucoseneverliesLinkedIn: https://www.linkedin.com/company/theglucoseneverliesLinkedIn John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/LinkedIn Anjanee Kohli: https://www.linkedin.com/in/anjanee-kohli-chohan-1b22a217b/Instagram Anjanee Kohli: https://www.instagram.com/anjanee.dietitianX: https://twitter.com/GlucoseNLiesDisclaimerThis podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.The Glucose Never Lies® is independent by designWe do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:Buying the GNL a Coffee:https://buymeacoffee.com/gnlfreeEnquiriesCollaboration: John Pemberton — john@theglucoseneverlies.comCreatives: Anjanee Kohli — anj@theglucoseneverlies.comFollow The Glucose Never Lies®Website: https://theglucoseneverlies.com/Instagram: https://www.instagram.com/theglucoseneverliesLinkedIn: https://www.linkedin.com/company/theglucoseneverliesLinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/X: https://twitter.com/GlucoseNLiesDisclaimer This content is for informational purposes only and does not constitute medical advice.© The Glucose Never Lies Ltd. All rights reserved.
Transcribe →
Episode 39: Abbott FreeStyle Libre - Accuracy, Simplicity and What's Next
Apr 2700:41:34Tap to summarizeSuggest guests or get in contactMichael Skarlatos from Abbott UK Medical Affairs joins John Pemberton for the second manufacturer episode of the CGM Series. A former diabetes specialist dietitian at University Hospitals of Leicester, Michael brings real clinical experience to an honest breakdown of the FreeStyle Libre 2 Plus and 3 Plus.This episode covers:- Why Abbott accuracy data qualifies these sensors for insulin dosing: ICGM approved, 20/20 performance ~95-96%, outside-40/40 error rate 0.2%- What 70% smaller means in practice: form factor, stigma, and the all-in-one applicator on Libre 3 Plus- Pump integrations now and the roadmap: CamAPS FX, Omnipod 5, and what is coming- Libreview: why Abbott moved off Glooko and what population health management enables- Libreview Pro in SystmOne and EMIS with SNOMED-coded CGM metrics- A critical data nuance: glucose measured every minute on the patient app but recorded every 5 minutes in clinical downloads- Continuous ketone monitoring: what Abbott has in development and who benefits mostCHAPTERS00:00 Introduction and CGM Series overview00:57 Michaels background and Leicester NHS Trust02:25 Moving from NHS to Abbott Medical Affairs03:27 Accuracy credentials: ICGM approval and 20/20 performance05:44 FreeStyle Libre 3 Plus: size and form factor09:25 Pump integrations: CamAPS FX, Omnipod 5, and the roadmap10:19 ICGM interoperability: US vs CE marking in Europe12:05 Fifteen-day wear period12:28 Abbott market history: free samples and patient-led adoption14:04 Simplicity of onboarding and multi-language support16:58 Starter clinics: taking onboarding off the HCP19:33 Libreview and population health management23:21 EHR integration, SNOMED codes, and QOF implications25:46 Practical tips: Bluetooth connectivity and the app cache29:23 Minute-by-minute data vs five-minute trend recording30:58 Low glucose event thresholds and hypo underreporting31:42 Continuous ketone monitoring: what is coming from Abbott37:52 CGM beyond type 1 and patient advocacy40:17 Closing thoughtsLINKSShow notes: https://theglucoseneverlies.com/episode-38-freestyle-libre-abbott/YouTube: https://youtu.be/IW1sa5APHU8CGM Series: https://theglucoseneverlies.com/10-13-cgm-series/GNL Explorers: https://theglucoseneverlies.com/gnl-grace/Buzzsprout: https://www.buzzsprout.com/2451357/18982022Apple Podcasts: https://podcasts.apple.com/gb/podcast/the-glucose-never-lies/id1795741144Spotify: https://open.spotify.com/show/2MlGlz2G8LsbDnuGtAh77WThis content is for educational exploration only. Not medical advice.Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.DisclaimerThis podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.The Glucose Never Lies® is independent by designWe do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:Buying the GNL a Coffee:https://buymeacoffee.com/gnlfreeEnquiriesCollaboration: John Pemberton — john@theglucoseneverlies.comCreatives: Anjanee Kohli — anj@theglucoseneverlies.comFollow The Glucose Never Lies®Website: https://theglucoseneverlies.com/Instagram: https://www.instagram.com/theglucoseneverliesLinkedIn: https://www.linkedin.com/company/theglucoseneverliesLinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/X: https://twitter.com/GlucoseNLiesDisclaimer This content is for informational purposes only and does not constitute medical advice.© The Glucose Never Lies Ltd. All rights reserved.
Transcribe →
Episode 38: Q1 2026 Quarterly Review, GNL Grace, the Explorers, and What Changed
Apr 2000:36:39Tap to summarizeSuggest guests or get in contactThree months ago, GNL was a website full of excellent content that was genuinely hard to find. In Episode 38, John Pemberton and Creative Director Anjanee Kohli talk through what happened next: a complete website rebuild, five interactive explorers, the launch of GNL Grace, and the evidence base behind it, drawn from approximately 500,000 patient-days across roughly 1,300 people living with diabetes over more than 10 years.In this episode:CGM guide update and the five-out-of-five accuracy chartHow the five GNL Explorers work and how clinicians are using them in practiceGNL Grace: a bounded AI educational advisor built on 2,000 curated citationsGrace: a 30-day free trial for everyone, then Personal at £5 a month and HCP at £20 a monthReal-world validation: approximately 500,000 patient-days across roughly 1,300 people living with diabetes over more than 10 yearsWhy the skill of the future in healthcare is compassion, not knowledgePhil Hayes joining as Technical DirectorGNL merch and the Diabetes UK giveawayChapters:00:00 Introduction01:55 GNL Grace announcement02:32 CGM guide and accuracy chart05:30 Phil Hayes and the explorer infrastructure09:40 GNL Grace: the six-layer bounded AI10:50 Grace tiers explained13:31 Grace Max: manuscript-grade output17:31 Real-world validation: the evidence base behind Grace19:58 The skill of the future is compassion30:09 What went wrong and lessons learned35:06 GNL merch36:10 ClosingLinks:Show notes: theglucoseneverlies.com/episode-38-quarterly-reviewGNL Grace: theglucoseneverlies.com/gnl-graceGNL Explorers: theglucoseneverlies.com/gnl-explorersCGM Series hub: theglucoseneverlies.com/10-13-cgm-seriesHost: John Pemberton. Director of Creativity: Anjanee Kohli.This content is for educational exploration only. It is not medical advice and cannot replace individual clinical guidance from your diabetes care team.Support GNL: https://www.buymeacoffee.com/gnlfreeThe Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.DisclaimerThis podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.The Glucose Never Lies® is independent by designWe do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:Buying the GNL a Coffee:https://buymeacoffee.com/gnlfreeEnquiriesCollaboration: John Pemberton — john@theglucoseneverlies.comCreatives: Anjanee Kohli — anj@theglucoseneverlies.comFollow The Glucose Never Lies®Website: https://theglucoseneverlies.com/Instagram: https://www.instagram.com/theglucoseneverliesLinkedIn: https://www.linkedin.com/company/theglucoseneverliesLinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/X: https://twitter.com/GlucoseNLiesDisclaimer This content is for informational purposes only and does not constitute medical advice.© The Glucose Never Lies Ltd. All rights reserved.
Transcribe →
Episode 37: Dexcom G7 and ONE+| Adam Dawes | GNL Podcast
Apr 1300:53:42Tap to summarizeSuggest guests or get in contactMost people with T1D have switched their CGM high alert off. Not because they do not care - because it goes off every time they eat and there is nothing they can do about it. Episode 37 is about what Dexcom built to fix that.Adam Dawes, Senior Medical Affairs Manager at Dexcom UK and Ireland - and a former paediatric diabetes nurse specialist - joins John Pemberton for the third manufacturer episode of the CGM Series. An honest clinical conversation about the Dexcom G7 and ONE+, what separates them, and where Dexcom is heading next.This episode covers:- Dexcom G7 vs Dexcom ONE+: same hardware platform, different software, and what that means for matching the right sensor to the right patient- Delay 1st Alert: why it is one of the most underused alerts in CGM, how it eliminates alarm fatigue without reducing safety, and how John uses it himself- AID integrations: Tandem T:slim X2, Omnipod 5, mylife, and the Tandem Mobi- CGM for type 2 diabetes: the biofeedback argument and why immediate glucose feedback changes behaviour in ways a quarterly HbA1c never can- The Dexcom roadmap from ATTD 2026: 15-day sensor, Dexcom G8 next generation sensor, EPIC integration, Clarity updates, and generative AI- Why insulin dosing will never be a commodity market - and what people with T1D need to understand as new CGMs enter the UK- The FDA manufacturing findings: what happened, how Dexcom responded, and why the new Ireland factory mattersShow notes: https://theglucoseneverlies.com/episode-37-dexcom-g7-one-plus/ | CGM Series: https://theglucoseneverlies.com/10-13-cgm-series/Have more questions about CGM, the Dexcom G7 or ONE+? Ask GNL Grace: https://theglucoseneverlies.com/gnl-grace/Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.DisclaimerThis podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.The Glucose Never Lies® is independent by designWe do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:Buying the GNL a Coffee:https://buymeacoffee.com/gnlfreeEnquiriesCollaboration: John Pemberton — john@theglucoseneverlies.comCreatives: Anjanee Kohli — anj@theglucoseneverlies.comFollow The Glucose Never Lies®Website: https://theglucoseneverlies.com/Instagram: https://www.instagram.com/theglucoseneverliesLinkedIn: https://www.linkedin.com/company/theglucoseneverliesLinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/X: https://twitter.com/GlucoseNLiesDisclaimer This content is for informational purposes only and does not constitute medical advice.© The Glucose Never Lies Ltd. All rights reserved.
Transcribe →
36: CGM Series - CGM Accuracy, DSN Reality Checks and the Future of Diabetes Technology
Mar 2900:51:24Tap to summarizeSuggest guests or get in contactCGM Series | The Glucose Never Lies® PodcastThree of the UK's leading diabetes specialist nurses on why CE marking is not a quality standard for CGM accuracy, why data sufficiency must come before device comparison, and what ATTD 2025 revealed about where diabetes technology is heading. A frank, clinical conversation grounded in years of front-line practice — and the story of how the DSN Forum's five-point accuracy scoring system was built.In this episode:Why the DSN Forum created its CGM comparison chart and how it has evolvedWhy CE marking is not a quality standard for CGM accuracyHow the five-point accuracy scoring system works and what it requires from a deviceWhy only four devices currently meet the data sufficiency standardWhat 20/20 and 40/40 agreement rates mean in real clinical termsWhy everyone using CGM for insulin decisions still needs a working finger-prick meterThe calibration debate: does the option to calibrate add safety or risk?What ATTD 2025 revealed about fully closed loop systems — and who may not benefitThe case for GLP-1 in type 1 diabetes and why priority access mattersAbbott's continuous ketone monitor: opportunity, unknowns, and risksAID system optimisation, insulin on board, and the GNL AID System ExplorerChapters:00:00 — Introduction: meeting Amanda, Beth and Tamsin02:14 — Why the DSN Forum CGM comparison chart was created06:47 — Turning complex CGM evidence into a practical scoring system16:23 — How CGM choice works in real clinical settings20:36 — Why finger-prick testing still matters — and the calibration debate29:26 — What stood out at ATTD 202544:03 — AID systems, insulin on board, and the GNL AID optimiser49:49 — Where to find the DSN Forum, the chart, and closing thoughtsGuests: Amanda Williams (Lead Diabetes Nurse, East Kent), Beth Kelly (Clinical Lead DSN, Wiltshire), Tamsin Fletcher-Salt (Lead DSN, University Hospital North Midlands). All core members of the Diabetes Specialist Nurse Forum UK.Links:Full show notes: https://theglucoseneverlies.com/episode-36-cgm-accuracy-dsn-forum/DSN Forum CGM Comparison Chart: https://www.diabetesspecialistnurseforumuk.co.uk/new-cgm-comparison-chartCGM Guide Part 2 — Assessing CGM Accuracy: https://theglucoseneverlies.com/assessing-cgm-accuracy-performance/GNL AID System Explorer: https://theglucoseneverlies.com/aid-system-explorer/Episode 35 — Professor Othmar Moser on CGM Study Design: https://theglucoseneverlies.com/episode-35-cgm-series-the-importance-of-cgm-accuracy-and-study-design-with-professor-othmar-moser/Educational purposes only. Not medical advice. Always work with your diabetes care team.Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.DisclaimerThis podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.The Glucose Never Lies® is independent by designWe do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:Buying the GNL a Coffee:https://buymeacoffee.com/gnlfreeEnquiriesCollaboration: John Pemberton — john@theglucoseneverlies.comCreatives: Anjanee Kohli — anj@theglucoseneverlies.comFollow The Glucose Never Lies®Website: https://theglucoseneverlies.com/Instagram: https://www.instagram.com/theglucoseneverliesLinkedIn: https://www.linkedin.com/company/theglucoseneverliesLinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/X: https://twitter.com/GlucoseNLiesDisclaimer This content is for informational purposes only and does not constitute medical advice.© The Glucose Never Lies Ltd. All rights reserved.
Transcribe →
35: CGM Series - The Importance of CGM Accuracy and Study Design with Professor Othmar Moser
Mar 2300:59:35Tap to summarizeSuggest guests or get in contactCGM Series | The Glucose Never Lies® PodcastCGM accuracy is usually described with a single number: MARD. But a low MARD can hide significant risk if the study behind it was poorly designed. Professor Othmar Moser — one of the leading independent CGM accuracy researchers — explains what study design actually determines, why meal and insulin challenges are non-negotiable, and what people with type 1 diabetes and clinicians should look for when evaluating any accuracy claim.In this episode:What MARD is and why it misleads when used in isolationThe five study design questions that determine what accuracy data actually meansWhy 20/20 and 40/40 agreement rates reveal what MARD cannotWhy meal and insulin challenges are essential for real-world accuracy testingWhat CE marking does and does not guarantee about CGM performanceWhy peer-reviewed, independent evidence is the gold standard — and how little of what is cited meets itHow study design quality shapes what we actually know about CGM riskProfessor Moser's perspective as a researcher who designs and runs these studiesGuest: Professor Othmar Moser, Medical University of Graz, Austria. Leading figure in independent CGM accuracy study design and insulin-related exercise physiology research in type 1 diabetes.Links:Full show notes: https://theglucoseneverlies.com/episode-35-cgm-series-the-importance-of-cgm-accuracy-and-study-design-with-professor-othmar-moser/CGM Guide Part 2 — Assessing CGM Accuracy: https://theglucoseneverlies.com/assessing-cgm-accuracy-performance/CGM Guide Part 1 — How to Choose a CGM: https://theglucoseneverlies.com/select-continuous-glucose-monitor-cgm-understanding/Episode 36 — DSN Forum: CGM Accuracy and ATTD 2025: https://theglucoseneverlies.com/episode-36-cgm-accuracy-dsn-forum/Watch on YouTube: https://youtu.be/zTdTps42kQ8Educational purposes only. Not medical advice. Always work with your diabetes care team.Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.DisclaimerThis podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.The Glucose Never Lies® is independent by designWe do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:Buying the GNL a Coffee:https://buymeacoffee.com/gnlfreeEnquiriesCollaboration: John Pemberton — john@theglucoseneverlies.comCreatives: Anjanee Kohli — anj@theglucoseneverlies.comFollow The Glucose Never Lies®Website: https://theglucoseneverlies.com/Instagram: https://www.instagram.com/theglucoseneverliesLinkedIn: https://www.linkedin.com/company/theglucoseneverliesLinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/X: https://twitter.com/GlucoseNLiesDisclaimer This content is for informational purposes only and does not constitute medical advice.© The Glucose Never Lies Ltd. All rights reserved.
Transcribe →
34 — Building High-Performance Type 1 Diabetes Care: Technology, Targets, and Equity (Dr Peter Adolfsson)
Mar 400:51:02Tap to summarizeSuggest guests or get in contactHow do some countries consistently achieve lower HbA1c and better outcomes in type 1 diabetes while others struggle — even with the same technologies?In this episode, John Pemberton speaks with Dr Peter Adolfsson, paediatric diabetologist in Sweden and lead author of the ISPAD 2022 Exercise Guidelines, about what actually drives population-level improvements in type 1 diabetes care.Full show notes:https://theglucoseneverlies.com/episode-34-building-high-performance-type-1-diabetes-care-technology-targets-and-equity-dr-peter-adolfsson/KEY TOPICS• How Sweden’s national diabetes registry drives accountability and rapid improvement • Why structured onboarding and early follow-up are essential for CGM and AID success • The role of national collaboration between clinics to share best practice • Why the highest HbA1c group should often be first in line for AID systems • Moving toward time in tight range (3.9–7.8 mmol/L) as the next clinical target • Equity in diabetes technology: checking subconscious bias with real data • Why celebrating small improvements builds long-term engagementWHAT YOU’LL LEARN✓ Why early investment in education and follow-up changes long-term outcomes ✓ How national benchmarking between clinics improves diabetes care ✓ Why targets matter — changing what you measure changes what improves ✓ How to use AID systems strategically for people struggling with bolusing ✓ Why the first two years after diagnosis are a critical window for glycaemic outcomes ✓ The importance of psychology, social support, and multidisciplinary teamsFUTURE OF TYPE 1 DIABETES CARE• AI-supported platforms that analyse CGM data continuously • Clinics responding earlier when glucose control deteriorates • Personalised therapy combining insulin with adjunct treatments (e.g., GLP-1RA) • More flexible care models where stable patients may need fewer clinic visitsSupport GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.DisclaimerThis podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.The Glucose Never Lies® is independent by designWe do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:Buying the GNL a Coffee:https://buymeacoffee.com/gnlfreeEnquiriesCollaboration: John Pemberton — john@theglucoseneverlies.comCreatives: Anjanee Kohli — anj@theglucoseneverlies.comFollow The Glucose Never Lies®Website: https://theglucoseneverlies.com/Instagram: https://www.instagram.com/theglucoseneverliesLinkedIn: https://www.linkedin.com/company/theglucoseneverliesLinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/X: https://twitter.com/GlucoseNLiesDisclaimer This content is for informational purposes only and does not constitute medical advice.© The Glucose Never Lies Ltd. All rights reserved.
Transcribe →